InVitae Corp (NASDAQ:NVTA) is scheduled to be releasing its 6/30/2017 earnings data after the market closes on Monday, August 7th. Analysts expect InVitae Corp to post earnings of ($0.62) per share for the quarter.
InVitae Corp (NASDAQ:NVTA) last posted its quarterly earnings results on Tuesday, May 9th. The medical research company reported ($0.64) EPS for the quarter, topping analysts’ consensus estimates of ($0.68) by $0.04. The company had revenue of $10.34 million for the quarter, compared to analysts’ expectations of $10.90 million. InVitae Corp had a negative net margin of 260.48% and a negative return on equity of 119.10%. InVitae Corp’s revenue was up 161.1% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($0.80) EPS. On average, analysts expect InVitae Corp to post $-2.39 EPS for the current fiscal year and $-1.63 EPS for the next fiscal year.
Shares of InVitae Corp (NVTA) opened at 10.34 on Friday. InVitae Corp has a 12-month low of $5.76 and a 12-month high of $11.88. The company’s market cap is $437.53 million. The company has a 50 day moving average of $9.49 and a 200-day moving average of $9.75.
Several equities research analysts recently issued reports on the stock. BidaskClub cut shares of InVitae Corp from a “hold” rating to a “sell” rating in a report on Thursday, July 27th. ValuEngine upgraded shares of InVitae Corp from a “strong sell” rating to a “sell” rating in a report on Friday, June 2nd. Finally, Zacks Investment Research cut shares of InVitae Corp from a “hold” rating to a “sell” rating in a report on Tuesday, July 18th. Three analysts have rated the stock with a sell rating, one has given a hold rating and three have given a buy rating to the company. The stock currently has an average rating of “Hold” and a consensus target price of $12.69.
InVitae Corp Company Profile
Invitae Corporation utilizes an integrated portfolio of laboratory processes, software tools and informatics capabilities to process deoxyribonucleic acid (DNA)-containing samples, analyze information about patient-specific genetic variation and generate test reports for clinicians and their patients.
Receive News & Ratings for InVitae Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for InVitae Corp and related companies with MarketBeat.com's FREE daily email newsletter.
